Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Influence of prenatal EGCG treatment and Dyrk1a dosage reduction on craniofacial features associated with Down syndrome.

Human molecular genetics - 15 Nov 2016

McElyea Samantha D, Starbuck John M, Tumbleson-Brink Danika M, Harrington Emily, Blazek Joshua D, Ghoneima Ahmed, Kula Katherine, Roper Randall J

Abstract excerpt

Trisomy 21 (Ts21) affects craniofacial precursors in individuals with Down syndrome (DS). The resultant craniofacial features in all individuals with Ts21 may significantly affect breathing, eating and speaking. Using mouse models of DS, we have traced the origin of DS-associated craniofacial abnormalities to deficiencies in neural crest cell (NCC) craniofacial precursors early in development. Hypothetically,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Catechin
Share to Craniofacial Abnormalities

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Down Syndrome

Share to Dyrk Kinases

Share to Gene Dosage

Share to Phosphorylation

Share to Protein Serine-Threonine Kinases

Share to Protein-Tyrosine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 28172997
DOI: 10.1093/hmg/ddw309
PMCID: PMC6049609

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Influence of prenatal EGCG treatment and Dyrk1a dosage reduction on craniofacial features associated with Down syndrome.PMID 28172997Read ↗

Targeting trisomic treatments: optimizing Dyrk1a inhibition to improve Down syndrome deficitsSemantic proximity Read ↗

Rescue of the abnormal skeletal phenotype in Ts65Dn Down syndrome mice using genetic and therapeutic modulation of trisomicDyrk1aSemantic proximity Read ↗

DYRK1A Protein, A Promising Therapeutic Target to Improve Cognitive Deficits in Down SyndromeSemantic proximity Read ↗

Pleiotropic effects of trisomy and pharmacologic modulation on structural, functional, molecular, and genetic systems in a Down syndrome mouse modelSemantic proximity Read ↗

Epigallocatechin‐3‐gallate, a DYRK1A inhibitor, rescues cognitive deficits in <scp>D</scp>own syndrome mouse models and in humansSemantic proximity Read ↗

Prenatal treatment with EGCG enriched green tea extract rescues GAD67 related developmental and cognitive defects in Down syndrome mouse modelsSemantic proximity Read ↗

Epigallocatechin-3-Gallate Improves Facial Dysmorphology Associated with Down SyndromeSemantic proximity Read ↗

DYRK1A, a Dosage-Sensitive Gene Involved in Neurodevelopmental Disorders, Is a Target for Drug Development in Down SyndromeSemantic proximity Read ↗

The Role of Goldilocks Protein Kinase DYRK1A in Embryonic DevelopmentSemantic proximity Read ↗

Epigallocatechin-3-gallate (EGCG) consumption in the Ts65Dn model of Down syndrome fails to improve behavioral deficits and is detrimental to skeletal phenotypes.Semantic proximity Read ↗

Green Tea Polyphenols Rescue of Brain Defects Induced by Overexpression of DYRK1ASemantic proximity Read ↗

Sex-specific developmental phenotypes and their response to neonatal <i>Dyrk1a</i> reduction in the Ts65Dn Down syndrome mouse modelSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.